Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma

Terada,Takayuki; Tabata,Chiharu; Tabata,Rie; Okuwa,Hisaya; Kanemura,Shingo; Shibata,Eisuke; Nakano,Takashi

doi:10.3892/etm.2012.572

Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma

Authors:
- Takayuki Terada
- Chiharu Tabata
- Rie Tabata
- Hisaya Okuwa
- Shingo Kanemura
- Eisuke Shibata
- Takashi Nakano
View Affiliations

Affiliations: Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan, Department of Internal Medicine, Hyogo Prefectural Tsukaguchi Hospital, Hyogo, Japan
Published online on: May 11, 2012 https://doi.org/10.3892/etm.2012.572
Pages: 197-200

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure. MPM has a limited response to conventional chemotherapy and radiotherapy, thus early diagnosis of MPM is extremely critical. CT scans have limited accuracy in the differentiation between benign and malignant pleural disease. Several studies have reported that 18-fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the assessment of thoracic malignancy such as lung cancer. Here, we investigated the clinical utility of PET in patients with MPM. The maximum SUV (SUVmax) of 18F-FDG was measured in 47 MPM patients and 29 non-MPM patients including those with pleural thickening. We demonstrated that patients with MPM had significantly higher SUVmax levels than a population with non-malignant pleural disease. The Kaplan-Meier method revealed significant differences in overall survival between groups with SUVmax levels lower and higher than the assumed cut‑off. Our data suggest that SUVmax levels are useful as an aid for diagnosis and prognosis of MPM.

View Figures

View References

1.	Robinson BW, Musk AW and Lake RA: Malignant mesothelioma. Lancet. 366:397–408. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005. View Article : Google Scholar : PubMed/NCBI
3.	Wagner JC, Sleggs CA and Marchand P: Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 17:260–271. 1960.PubMed/NCBI
4.	Selikoff IJ, Hammond EC and Seidman H: Latency of asbestos disease among insulation workers in the United States and Canada. Cancer. 15:2736–2740. 1980. View Article : Google Scholar : PubMed/NCBI
5.	Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Nowak AK, Lake RA, Kindler HL, et al: New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol. 29:82–96. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Leung AN, Müller NL and Miller RR: CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol. 154:487–492. 1990. View Article : Google Scholar : PubMed/NCBI
8.	Müller NL: Imaging of the pleura. Radiology. 186:297–309. 1993.
9.	Rigo P, Paulus P, Kaschten BJ, et al: Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 23:1641–1674. 1996. View Article : Google Scholar : PubMed/NCBI
10.	Gupta NC, Frank AR, Dewan NA, et al: Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 184:441–444. 1992.
11.	Patz EF Jr, Lowe VJ, Hoffman JM, et al: Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology. 188:487–490. 1993. View Article : Google Scholar : PubMed/NCBI
12.	Bénard F, Sterman D, Smith RJ, et al: Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 114:713–722. 1998.PubMed/NCBI
13.	Bénard F, Sterman D, Smith RJ, et al: Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med. 40:1241–1245. 1999.
14.	Flores RM, Akhurst T, Gonen M, et al: Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 132:763–768. 2006. View Article : Google Scholar : PubMed/NCBI
15.	Yildirim H, Metintas M, Entok E, et al: Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol. 4:1480–1484. 2009. View Article : Google Scholar
16.	Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 108:1122–1128. 1995. View Article : Google Scholar : PubMed/NCBI
17.	Heelan RT, Rusch VW, Begg CB, et al: Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol. 172:1039–1047. 1999. View Article : Google Scholar : PubMed/NCBI
18.	Patz EF Jr, Shaffer K, Piwnica-Worms DR, et al: Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol. 159:961–966. 1992. View Article : Google Scholar : PubMed/NCBI